Biotech firm Septerna beats Q4 revenue expectations, net loss narrows

Septerna

09/03/2026 20:22

Overview

Biotechnology firm's Q4 revenue beat analyst expectations

Company reported net loss of $10.7 mln for Q4, down from $20.7 mln last year

SEP-631 Phase 1 results support Phase 2b development in CSU

Outlook

Cash runway expected to support operations into 2029

Result Drivers

SEP-631 PHASE 1 RESULTS - Positive Phase 1 results for SEP-631 demonstrated safety and efficacy, supporting advancement to Phase 2b trials

Research and development (R&D) expenses were $31.9 million for the fourth quarter of 2025

Cash, cash equivalents, and marketable securities totaled $548.7 million as of December 31, 2025, compared to $420.8 million as of December 31, 2024

REVENUE INCREASE - Revenue increased significantly due to collaboration payments, including a $195 mln upfront payment from Novo Nordisk

Company press release: ID:nGNXpgQjP

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$24.12 mln
$17.33 mln (6 Analysts)
Q4 Net Income
-$10.74 mln
Q4 Income From Operations
-$16.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Septerna Inc is $40.00, about 39% above its March 6 closing price of $28.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)